Eylea Approval Expanded to Include Diabetic Retinopathy

March 25, 2015 9:00 PM

17 0

WEDNESDAY, March 25, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release.

Affecting more than 29 million people in the U.S., diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness, the FDA said. Among some people who have vision-impairing diabetic macular edema, diabetic retinopathy can spur the growth of abnormal blood vessels on th...

Read more

To category page